Analysts predict that Corvus Pharmaceuticals Inc (NASDAQ:CRVS) will report earnings of ($0.46) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.45). Corvus Pharmaceuticals reported earnings of ($0.62) per share during the same quarter last year, which suggests a positive year over year growth rate of 25.8%. The firm is scheduled to report its next earnings report on Thursday, November 1st.

On average, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($1.98) per share for the current fiscal year, with EPS estimates ranging from ($2.02) to ($1.94). For the next financial year, analysts forecast that the business will post earnings of ($1.79) per share, with EPS estimates ranging from ($1.88) to ($1.70). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, August 2nd. The company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.24.

A number of analysts have weighed in on CRVS shares. Zacks Investment Research cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 13th. BidaskClub cut shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, May 17th. ValuEngine raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 26th. Finally, Jefferies Financial Group started coverage on shares of Corvus Pharmaceuticals in a report on Tuesday, June 5th. They set a “buy” rating and a $17.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $13.67.

Several hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. increased its holdings in shares of Corvus Pharmaceuticals by 48.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,900 shares of the company’s stock worth $285,000 after acquiring an additional 8,400 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Corvus Pharmaceuticals by 35.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 37,099 shares of the company’s stock worth $407,000 after acquiring an additional 9,782 shares during the period. Deutsche Bank AG increased its holdings in shares of Corvus Pharmaceuticals by 118.1% in the 4th quarter. Deutsche Bank AG now owns 19,058 shares of the company’s stock worth $196,000 after acquiring an additional 10,320 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Corvus Pharmaceuticals by 129.3% in the 2nd quarter. Acadian Asset Management LLC now owns 21,494 shares of the company’s stock worth $236,000 after acquiring an additional 12,119 shares during the period. Finally, Rhumbline Advisers acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter worth about $147,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:CRVS traded down $0.05 on Friday, reaching $9.37. 31,726 shares of the company’s stock were exchanged, compared to its average volume of 70,484. Corvus Pharmaceuticals has a fifty-two week low of $7.42 and a fifty-two week high of $17.64.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Story: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.